10x Genomics Stock Shares Owned By Institutions
| TXG Stock | USD 13.68 0.60 4.59% |
Fundamental analysis of 10X Genomics allows traders to better anticipate movements in 10X Genomics' stock price by examining its financial health and performance throughout various phases of its business cycle.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. 10X Genomics Company Shares Owned By Institutions Analysis
10X Genomics' Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
More About Shares Owned By Institutions | All Equity Analysis
Shares Held by Institutions | = | Funds and Banks | + | Firms |
Current 10X Genomics Shares Owned By Institutions | 98.08 % |
Most of 10X Genomics' fundamental indicators, such as Shares Owned By Institutions, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, 10X Genomics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
| Competition |
Based on the latest financial disclosure, 98% of 10X Genomics are shares owned by institutions. This is 119.71% higher than that of the Life Sciences Tools & Services sector and significantly higher than that of the Health Care industry. The shares owned by institutions for all United States stocks is 150.14% lower than that of the firm.
10X Shares Owned By Institutions Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses 10X Genomics' direct or indirect competition against its Shares Owned By Institutions to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of 10X Genomics could also be used in its relative valuation, which is a method of valuing 10X Genomics by comparing valuation metrics of similar companies.10X Genomics is currently under evaluation in shares owned by institutions category among its peers.
10X Fundamentals
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.25) % | ||||
| Operating Margin | (0.31) % | ||||
| Current Valuation | 1.26 B | ||||
| Shares Outstanding | 111.09 M | ||||
| Shares Owned By Insiders | 1.92 % | ||||
| Shares Owned By Institutions | 98.08 % | ||||
| Number Of Shares Shorted | 14.26 M | ||||
| Price To Book | 2.28 X | ||||
| Price To Sales | 2.58 X | ||||
| Revenue | 610.78 M | ||||
| Gross Profit | 427.01 M | ||||
| EBITDA | (133.99 M) | ||||
| Net Income | (182.63 M) | ||||
| Cash And Equivalents | 499.73 M | ||||
| Cash Per Share | 4.39 X | ||||
| Total Debt | 82.61 M | ||||
| Debt To Equity | 0.13 % | ||||
| Current Ratio | 5.65 X | ||||
| Book Value Per Share | 5.74 X | ||||
| Cash Flow From Operations | 6.66 M | ||||
| Short Ratio | 3.41 X | ||||
| Earnings Per Share | (1.30) X | ||||
| Price To Earnings To Growth | 0.13 X | ||||
| Target Price | 13.54 | ||||
| Number Of Employees | 1.31 K | ||||
| Beta | 2.03 | ||||
| Market Capitalization | 1.61 B | ||||
| Total Asset | 918.64 M | ||||
| Retained Earnings | (1.47 B) | ||||
| Working Capital | 466.75 M | ||||
| Net Asset | 918.64 M |
About 10X Genomics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze 10X Genomics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of 10X Genomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of 10X Genomics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether 10X Genomics is a strong investment it is important to analyze 10X Genomics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact 10X Genomics' future performance. For an informed investment choice regarding 10X Stock, refer to the following important reports:Check out 10X Genomics Piotroski F Score and 10X Genomics Altman Z Score analysis. For more detail on how to invest in 10X Stock please use our How to Invest in 10X Genomics guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Measuring and Control Equipment space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of 10X Genomics. If investors know 10X will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about 10X Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of 10X Genomics is measured differently than its book value, which is the value of 10X that is recorded on the company's balance sheet. Investors also form their own opinion of 10X Genomics' value that differs from its market value or its book value, called intrinsic value, which is 10X Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because 10X Genomics' market value can be influenced by many factors that don't directly affect 10X Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between 10X Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if 10X Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, 10X Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.